Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis

  • Home
  • 2022
  • February
  • 17
  • Bristol Myers Squibb Presents Interim Results from Long-Term Study Reinforcing Maintenance of Response and Safety Profile of Zeposia (ozanimod) in Patients with Moderately to Severely Active Ulcerative Colitis

Original Source

On February 17, 2022

Post navigation

Previous PostLincoln National Corporation's Board of Directors Declares Quarterly Cash Dividend
Next PostGlobal business development leader joining Entergy Texas

Related Post

August 12, 2022
  • Business News

Modification to the Methodology of the S&P ESG Leaders Indices

August 12, 2022
  • Business News

Modification to the Methodology of the S&P Carbon Control Index Series

August 12, 2022
  • Business News

MACOM Technology Solutions Holdings Set to Join S&P MidCap 400

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219